Detail Measurement of Pre-Prandial and Post-Prandial Blood Glucose during Imeglimin (Twymeeg) Treatment | Abstract

Asploro Journal of Biomedical and Clinical Case Reports

Asploro Journal of Biomedical and Clinical Case Reports

ISSN: 2582-0370

Article Type: Case Report

DOI: 10.36502/2023/ASJBCCR.6288

Asp Biomed Clin Case Rep. 2023 Mar 02;6(1):40-46

Kenji Hayashi1, Hiroshi Bando1,2,3iD*, Kazuya Miki1, Misaki Hamai1, Tatsuo Yasuoka1
1Hayashi Hospital, Tokushima, Japan
2Tokushima University/Medical research, Tokushima, Japan
3Japan Low Carbohydrate Diet Promotion Association (JLCDPA), Kyoto, Japan

Corresponding Author: Hiroshi BANDO, MD, PhD, FACP ORCID iD
Address: Tokushima University /Medical Research, Nakashowa 1-61, Tokushima 770-0943, Japan.
Received date: 06 February 2023; Accepted date: 24 February 2023; Published date: 02 March 2023

Citation: Hayashi K, Bando H, Miki K, Hamai M, Yasuoka T. Detail Measurement of Pre-Prandial and Post-Prandial Blood Glucose during Imeglimin (Twymeeg) Treatment. Asp Biomed Clin Case Rep. 2023 Mar 02;6(1):40-46.

Copyright © 2023 Hayashi K, Bando H, Miki K, Hamai M, Yasuoka T. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.

Keywords: Imeglimin (Twymeeg), Nathan’s Equation, Low Carbohydrate Diet, Trials of Imeglimin for Efficacy and Safety, Oral Hypoglycemic Agent, Twymeeg

Abbreviations: LCD: Low Carbohydrate Diet; TIMES: Trials of Imeglimin for Efficacy and Safety; OHA: Oral Hypoglycemic Agent

Abstract

Background: Among oral hypoglycemic agents (OHAs), imeglimin (Twymeeg) would be in focus.
Case Presentation: The patient in this case is a 58-year-old female with a history of obesity and previous operations for posterior longitudinal ligament ossification. In early September 2022, she developed dizziness and a general feeling of unwellness, leading to a diagnosis of Type 2 Diabetes (T2D) with an HbA1c level of 11.1%.
Result: The patient was treated with a low carbohydrate diet (LCD) and Twymeeg, resulting in a significant decrease in HbA1c levels from 11.1% to 9.0%, 6.7%, and 5.9% over the course of three months. Pre-prandial and post-prandial blood glucose levels were measured with great accuracy.
Discussion and Conclusion: The administration of Twymeeg was found to be effective in reducing the patient’s HbA1c levels, and the relationship between HbA1c and glucose variability could be further investigated based on these results.

Facebooktwitterlinkedininstagramflickrfoursquaremail

asploro

Asploro Open Access Publications Limited